Microarrays Inc.

Microarrays Inc. is now offering custom laboratory services for gene expression projects.

New Product Watch


Microarrays Inc. this week launched three MI PathArray assays for studying targeted biological pathways. The new arrays cover pathways associated with apoptosis, growth factors, and inflammation.

The Huntsville, Ala.-based firm has tapped Cambio to distribute its products in the UK and Ireland; BioCat to cover Germany, Austria, and Switzerland; and Biosolutions to sell its arrays to customers in Cyprus, Greece, and other Balkan countries.

People in the News


Erik Holmlin, Edward Erickson, Andrew Jennings

The new corporate structure will allow Microarrays to "quickly and nimbly" respond to the growing needs of customers, especially in the diagnostics and healthcare markets, the company said in a statement.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.